In addition, a trend towards reduced hospitalisation was seen among those patients who had received gemifloxacin (2.3% vs. 6.3%;P= 0.059). It was suggested by Wilson et al. that the long-term benefits seen with gemifloxacin may relate to superior antimicrobial efficacy and decreased rates of hospitalisation for AECB resulting in significant economic implications